{"url":"https://lda.senate.gov/api/v1/filings/c70dc4f6-68de-4181-bf4e-74ab88194193/","filing_uuid":"c70dc4f6-68de-4181-bf4e-74ab88194193","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2021,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/c70dc4f6-68de-4181-bf4e-74ab88194193/print/","filing_document_content_type":"text/html","income":null,"expenses":"235000.00","expenses_method":"a","expenses_method_display":"Method A - Reporting amounts using LDA definitions only","posted_by_name":"Christopher Porter","dt_posted":"2021-04-21T00:01:14.723000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"3611 Valley Centre Drive","registrant_address_2":"Suite 300","registrant_different_address":true,"registrant_city":"San Diego","registrant_state":"CA","registrant_zip":"92130","registrant":{"id":401104190,"url":"https://lda.senate.gov/api/v1/registrants/401104190/","house_registrant_id":null,"name":"TRAVERE THERAPEUTICS","description":"Pharmaceuticals","address_1":"3611 Valley Centre Drive","address_2":"Suite 300","address_3":null,"address_4":null,"city":"San Diego","state":"CA","state_display":"California","zip":"92130","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CHRISTOPHER PORTER","contact_telephone":"+1 877-969-7879","dt_updated":"2026-01-23T12:45:17.477142-05:00"},"client":{"id":200929,"url":"https://lda.senate.gov/api/v1/clients/200929/","client_id":12,"name":"TRAVERE THERAPEUTICS","general_description":"Biopharmaceuticals","client_government_entity":false,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-08-15"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care.  Newborn Screening Saves Lives Act Reauthorization, H.R. 482, S 350.  FY 2022 CDC Appropriations for state newborn screening technical assistance.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Orphan Drug Tax Credit legislation and related rare disease research incentives","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Legislation regarding intellectual property and trademark issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"HR 366, Protecting Access to Post-COVID-19 Telehealth Act; other legislative proposals to ensure access to telehealth services","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Legislative proposals regarding drug pricing, value, and reimbursement.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"H.R. 1730, S. 670, Speeding Therapy Access Today Act of 2021; legislation regarding diagnosis and treatment of rare kidney diseases","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}